Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting

FLORHAM PARK, N.J., May 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced its participation in the Digestive Disease Week® (DDW) 2026 annual meeting, being held May 2–5 in Chicago, Illinois.

GlobeNewsWire • May 1, 2026

Phathom Pharmaceuticals, Inc. (PHAT) Q1 2026 Earnings Call Transcript

Phathom Pharmaceuticals, Inc. (PHAT) Q1 2026 Earnings Call Transcript

Seeking Alpha • Apr 30, 2026

Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

FLORHAM PARK, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.

GlobeNewsWire • Apr 30, 2026

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates

Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $1.07 per share a year ago.

Zacks Investment Research • Apr 30, 2026

Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026

Management to host conference call on Thursday, April 30, 2026, at 8:00 am EDT FLORHAM PARK, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, April 30, 2026, to report its first quarter 2026 financial results and provide a business update.

GlobeNewsWire • Apr 20, 2026

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in April: Raymond James 2026 Biotech Innovation Symposium in New York, NY Date: Tuesday, April 14, 2026 Management to participate in one-on-one meetings throughout the conference 25th Annual Needham Virtual Healthcare Conference Date: Wednesday, April 15, 2026Fireside Chat: 1:30 pm EDT Management to participate in one-on-one meetings throughout the conference To access the live webcast and archived recording of the event, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations.

GlobeNewsWire • Apr 6, 2026

Phathom Pharmaceuticals Upgraded by Barclays to Overweight With $18 Target

Barclays analyst Jenna Davidner upgraded Phathom Pharmaceuticals (NASDAQ:PHAT) to Overweight from Equal Weight on Friday, raising her price target to $18 from $16.

24/7 Wall Street • Mar 27, 2026

Phathom Pharmaceuticals, Inc. (PHAT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Phathom Pharmaceuticals, Inc. (PHAT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Seeking Alpha • Mar 11, 2026

Phathom Pharmaceuticals, Inc. (PHAT) Q4 2025 Earnings Call Transcript

Phathom Pharmaceuticals, Inc. (PHAT) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 26, 2026

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance

Over 1.1 million total VOQUEZNA® prescriptions filled to date $57.6 million in Q4 net revenues; $175.1 million in FY 2025 net revenues, a 217% increase from FY 2024 Q4 operating expenses of $55.9 million; non-GAAP operating expenses of $50.3 million and net cash usage of approximately $5.2 million, reflecting continued expense discipline Strengthened financial position through $130 million equity offering and modification of term debt Providing FY 2026 guidance; operating profitability expected beginning in Q3 2026 and for FY 2026 Management to host conference call today, February 26, 2026, at 8:00 a.m. EST FLORHAM PARK, N.J.

GlobeNewsWire • Feb 26, 2026